Case report: Severe allergic contact dermatitis to topical bufexamac requiring hospitalization

Bufexamac is a topical non‐steroidal anti‐inflammatory drug (NSAID) used as a local treatment for various dermatoses despite a propensity to cause severe allergic contact dermatitis (ACD) and a reported lack of efficacy. Bufexamac is still included in medicaments in countries such as Australia and Switzerland despite being banned in the European Union, the United States, New Zealand and Japan.

This article is protected by copyright. All rights reserved.

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2FfvrU0